ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

Core Insights - ZyVersa Therapeutics, Inc. has established a new Scientific Advisory Board (SAB) to support the development of its Inflammasome ASC Inhibitor IC 100, targeting obesity with metabolic complications [1][2] - IC 100 is expected to enhance weight loss and reduce chronic systemic inflammation associated with obesity, potentially addressing various inflammatory comorbidities [1] Company Overview - ZyVersa is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for inflammatory and renal diseases, with a significant market opportunity exceeding $100 billion [13] - The lead indication for IC 100 is obesity with metabolic complications, while another product, VAR 200, targets focal segmental glomerulosclerosis (FSGS) [13] Scientific Advisory Board Composition - The SAB includes five experts in obesity and metabolic diseases and four inflammasome specialists from the University of Miami Miller School of Medicine [1][2] - Notable members include: - Caroline M. Apovian, MD, Co-Director at Brigham and Women's Hospital [3] - Harold Bays, MD, Medical Director at Louisville Metabolic and Atherosclerosis Research Center [4] - Samuel Klein, MD, Director of the Center for Human Nutrition at Washington University [10] Mechanism of Action for IC 100 - IC 100 is a humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC, designed to mitigate both the initiation and perpetuation of inflammatory responses [12] - It works by binding to ASC, preventing inflammasome formation and blocking the activation of IL-1β, which is crucial in the inflammatory cascade [12]